Cellectar BioSciences News

Buy Rating on Cellectar Biosciences Backed by Strong Clinical Data and Promising Drug Pipeline

TipRanksMay 15 14:05 ET

Buy Rating on Cellectar Biosciences Backed by Promising Drug Candidate and Solid Financials

TipRanksMar 28 15:25 ET

Analysts Conflicted on These Healthcare Names: Cellectar Biosciences (CLRB), MiMedx Group (MDXG) and Marinus (MRNS)

TipRanksMar 28 07:50 ET

Cellectar Biosciences Analyst Ratings

BenzingaMar 28 07:32 ET

Buy Rating Affirmed for Cellectar Biosciences on Strong Clinical Results and Acquisition Potential

TipRanksMar 4 11:55 ET

Cellectar Biosciences Analyst Ratings

BenzingaMar 4 11:41 ET

Analysts Offer Insights on Healthcare Companies: Cellectar Biosciences (CLRB), Ionis Pharmaceuticals (IONS) and CVRx (CVRX)

TipRanksJan 22 14:51 ET

Analysts Offer Insights on Healthcare Companies: Cellectar Biosciences (CLRB) and Seres Therapeutics (MCRB)

TipRanksJan 9 12:00 ET

Oppenheimer Boosts Price Target on Cellectar Biosciences to $11 From $8, Maintains Outperform Rating

MT NewswiresJan 9 08:46 ET

Buy Rating Backed by Pivotal Trial Catalyst and Novel Drug Delivery Platform for Cellectar Biosciences

TipRanksJan 4 12:35 ET

Buy Rating on Cellectar Biosciences: Promising Clinical Study, Fast Track Designation and Strong Financial Position

TipRanksNov 3, 2023 14:06 ET

Oppenheimer Remains a Buy on Cellectar Biosciences (CLRB)

TipRanksNov 3, 2023 08:14 ET

Maxim Group Sticks to Their Buy Rating for Cellectar Biosciences (CLRB)

TipRanksSep 6, 2023 11:45 ET

Maxim Group Keeps Their Buy Rating on Cellectar Biosciences (CLRB)

TipRanksMay 5, 2023 14:45 ET

Oppenheimer Adjusts Cellectar Biosciences Price Target to $10 From $11, Maintains Outperform Rating

MT NewswiresMay 5, 2023 09:49 ET

Maxim Group Keeps Their Buy Rating on Cellectar Biosciences (CLRB)

TipRanksMar 10, 2023 14:50 ET

Maxim Group Keeps Their Buy Rating on Cellectar Biosciences (CLRB)

TipRanksMar 1, 2023 12:41 ET

Oppenheimer Adjusts Cellectar Biosciences Price Target to $12 From $47, Maintains Outperform Rating

MT NewswiresNov 4, 2022 10:53 ET

H.C. Wainwright Sticks to Their Buy Rating for Cellectar Biosciences (CLRB)

TipRanksNov 4, 2022 06:30 ET

Cellectar Biosciences Analyst Ratings

Benzinga Analyst RatingsNov 4, 2022 06:29 ET